The PREP Act’s Role in Shielding Big Pharma and Incentivizing Harmful COVID-19 Treatments
Imagine waking up one morning during the COVID-19 pandemic, eager to resume life as normal, and you decide to get the COVID-19 injection at your local pharmacy. In the name of “trusting the science,” you follow government guidelines and roll up your sleeve. But what happens when things go wrong? What happens if you’re suddenly […]
Pfizer Stock Posts Big Drop as Demand for COVID Shots and Paxlovid Dries Up
The value of shares in Pfizer, Inc. stock has dropped by over eight percent in recent weeks, bringing it to the lowest it has been in more than 10 years. The drop follows a recent announcement by the pharmaceutical company that it will post a decrease in revenue this year that will come in well […]
Only 14 Percent of American Adults Have Received Updated COVID Booster Shots
Only 13.9 percent of the U.S. adult population have rolled up their sleeves for the updated COVID-19 shot, according to the U.S. Centers for Disease Control and Prevention (CDC). The mRNA monovalent COVID booster shot, approved by the U.S. Food and Drug Administration (FDA) on Sept. 11, 2023 despite only being tested on mice, was […]
The Great Booster Bust
Despite eschewing much of social media, television, and trendy media stories, I still couldn’t avoid major mainstream news reports in 2021 and 2022 covering entertainment news about gormless Hollywood/social media types and political officials (who increasingly seem to preen about like Hollywood entertainers) making embarrassing spectacles of themselves getting their mRNA shots and/or gushing online […]
One in Five Paxlovid Users Experience COVID Rebound Infections
A new study published earlier this month suggests that people who took Pfizer’s Paxlovid (nirmatrelvir-ritonavir)—an antiviral drug treatment for COVID-19—are much more likely to experience reinfection than those who did not take the drug. The study, published in the Annals of Internal Medicine, reported that one in five people who take Paxlovid could experience rebound […]
Pfizer Will Charge Patients $1,390 for COVID Anti-Viral Paxlovid
Pfizer, Inc. plans to charge consumers more than double the price charged to the U.S. government for its COVID-19 anti-viral drug nirmatrelvir-ritonavir, sold under the brand name Paxlovid. A five-day course of the drug to treat COVID will soon cost patients $1,390. According to researchers, it costs Pfizer $13 to manufacture the supply of pills […]
